A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes

Similar documents
Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Questionnaire Health State Utility Values

Health Economics & Decision Science (HEDS) Discussion Paper Series

NICE DECISION SUPPORT UNIT

Formulário de acesso a dados do Registo Nacional de Doentes Reumáticos (Reuma.pt) da SPR,

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466

Making Value Based Pricing A Reality: Issue Panel

EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom

Critical appraisal of pharmacoeconomic studies comparing TNF-α antagonists for rheumatoid arthritis treatment

A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches

INTO ESTIMATES OF COST PER QALY: CASE STUDIES. December 2012

Technology appraisal guidance Published: 22 February 2012 nice.org.uk/guidance/ta247

Mapping the EORTC QLQ C-30 onto the EQ-5D Instrument: The Potential to Estimate QALYs without Generic Preference Data

NICE DSU TECHNICAL SUPPORT DOCUMENT 8: AN INTRODUCTION TO THE MEASUREMENT AND VALUATION OF HEALTH FOR NICE SUBMISSIONS

Japan Journal of Medicine

Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets

Cost-Utility Analysis (CUA), part II

To what extent do people prefer health states with higher values? A note on evidence from the EQ-5D valuation set

Bayesian Logistic Regression Modelling via Markov Chain Monte Carlo Algorithm

Health Services Research and Health Economics. Paul McCrone Institute of Psychiatry, King s College London

Cost-effectiveness of endovascular abdominal aortic aneurysm repair Michaels J A, Drury D, Thomas S M

Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M

1 Executive summary. Background

The response to the Committee request for additional analyses in section 1.4, MSD follows:

Quality review of a proposed EQ- 5D-5L value set for England

The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Bolin K, Lindgren B, Willers S

Exploring uncertainty in cost effectiveness analysis. Francis Ruiz NICE International (acknowledgements to: Benjarin Santatiwongchai of HITAP)

Cost-effectiveness of apremilast (Otezla )

HEDS Discussion Paper 08/02

HEDS Discussion Paper 06/12

Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets

This is the peer reviewed author accepted manuscript (post print) version of a published work that appeared in final form in:

Introduction to Machine Learning. Katherine Heller Deep Learning Summer School 2018

1. Comparative effectiveness of liraglutide

Mapping health outcome measures from a stroke registry to EQ-5D weights

Do Venous Procedures Have an Impact on Quality of Life? Mark H. Meissner, MD Professor of Surgery University of Washington Seattle, WA USA

Regional variation in health state preferences Does it exist, and does it matter?

Chapter 21 Multilevel Propensity Score Methods for Estimating Causal Effects: A Latent Class Modeling Strategy

Biotechnologically produced drugs as second-line therapy for rheumatoid arthritis 1

Health Economics 101: PPI prescriptions in the Emergency Room

Technology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547

Citation for published version (APA): Ebbes, P. (2004). Latent instrumental variables: a new approach to solve for endogeneity s.n.

Comments from Wyeth on the Assessment Report for the appraisal of Enbrel in RA General Comments

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

Advanced Bayesian Models for the Social Sciences. TA: Elizabeth Menninga (University of North Carolina, Chapel Hill)

Fitting discrete-data regression models in social science

Study population The study population comprised a hypothetical cohort of poorly reversible COPD patients with a history of exacerbations.

Kelvin Chan Feb 10, 2015

The EQ-5D is internationally one of the most

White Rose Research Online URL for this paper: Version: Accepted Version

Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D

Simponi / Simponi ARIA (golimumab)

Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value. Public Comments on Draft Report

Slides for Committee CIC redacted

Scottish Medicines Consortium

Cost-effectiveness analysis of biological treatments for rheumatoid arthritis Chiou C F, Choi J, Reyes C M

[Supplementary online-only material for Fiest KM, Fisk JD, Patten SB, et al: Fatigue and

Valuing health using visual analogue scales and rank data: does the visual analogue scale contain cardinal information?

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Your submission states that the adjusted indirect comparison methodology was based largely on the publication by Glenny et al

Russian Journal of Agricultural and Socio-Economic Sciences, 3(15)

Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340

adalimumab, 40mg/0.8mL, solution for injection (Humira ) SMC No. (858/13) AbbVie Ltd (previously part of Abbott)

Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta397

Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients

Putting the Patient in Patient Reported Outcomes: A Robust Methodology for Health Outcomes Assessment

Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries

Technology appraisal guidance Published: 14 December 2011 nice.org.uk/guidance/ta238

Use of GEEs in STATA

Cost-effectiveness of intraoperative facial nerve monitoring in middle ear or mastoid surgery Wilson L, Lin E, Lalwani A

Catherine A. Welch 1*, Séverine Sabia 1,2, Eric Brunner 1, Mika Kivimäki 1 and Martin J. Shipley 1

Outcomes assessed in the review The outcomes assessed in the review and used as model inputs were the incident rates of:

Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout

Economic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T

This is a repository copy of A comparison of the EQ-5D and the SF-6D across seven patient groups.

Critical Appraisal Skills. Professor Dyfrig Hughes Health Economist AWMSG

Technology appraisal guidance Published: 12 July 2017 nice.org.uk/guidance/ta455

A Description of the IVI-RA Model v1.0

Advanced Bayesian Models for the Social Sciences

Setting The setting was outpatient, secondary care. The economic study was carried out in the UK.

Technology appraisal guidance Published: 11 April 2018 nice.org.uk/guidance/ta517

Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients

Stated Preference Methods Research in Health Care Decision Making A Critical Review of Its Use in the European Regulatory Environment.

Survey of Smoking, Drinking and Drug Use (SDD) among young people in England, Andrew Bryant

Are preferences over health states informed?

EuroQol Working Paper Series

Technology appraisal guidance Published: 26 January 2016 nice.org.uk/guidance/ta375

Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain

6.3.5 Uncertainty Assessment

Lec 02: Estimation & Hypothesis Testing in Animal Ecology

Choice of EQ 5D 3L for Economic Evaluation of Community Paramedicine Programs Project

Basic Economic Analysis. David Epstein, Centre for Health Economics, York

Modelling the cost-effectiveness of anti-tnfs for the treatment of psoriatic arthritis PLEASE DO NOT REPRODUCE

Health Economics & Decision Science (HEDS) Discussion Paper Series

Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy

Pharmaceutical Statistics Journal Club 15 th October Missing data sensitivity analysis for recurrent event data using controlled imputation

Appendix. Lifetime extrapolation of data from the randomised controlled DiGEM trial

Mostly Harmless Simulations? On the Internal Validity of Empirical Monte Carlo Studies

Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? Konski A, Speier W, Hanlon A, Beck J R, Pollack A

Transcription:

A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes Mónica Hernández Alava, Allan Wailoo, Fred Wolfe and Kaleb Michaud

2 Introduction Mapping (or cross-walking ) is used to estimate a utility score/index from a different outcome measure - clinical trials without a preference based measure - Within PROMS agenda as performance indicators - Essential element of VBP Mapping involves: Estimating a relationship using a statistical model Predicting using the estimated model THIS IS ESSENTIALLY A STATISTICAL ISSUE!

3 EQ-5D-3L UK-tariff Descriptive system 11111, 21123 5 dimensions - mobility, self care, usual activities, pain, anxiety and depression 3 levels in each dimension- no problems, some problems, extreme problems 243 combinations Valuation (Dolan et al 1995) utility scores Analysis of preference data: 3000 individuals

4 Two general methods Direct: dependent variable utility/index scores 11213 -> 0.378 Indirect: dependent variables levels of descriptive system. Expected index score is calculated as a second step Response mapping

5 AIM: Estimate EQ-5D as a function of HAQ, Pain and other covariates direct & indirect methods US not-for-profit database N=100,398 (16k patients) Adults with RA diagnosis Classic EQ-5D (UK tariff) distribution Multimodal Peak at 1 Bounded top and bottom Gap between 1 and 0.883

Asthma (n=2,935) 30% 25% 20% 15% 10% 5% 0% 6 0.9 0.8 0.6 0.7 0.6 0.7 1 Proportion of Respondents -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 EQ-5D score Chest pain (n=679) 30% 25% 20% 15% 10% Proportion of Respondents 5% 0% -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 EQ-5D score Cronic obstructive pulmonary disease (n=185) 16% 14% 12% 10% 8% 6% 4% Proportion of Respondents 2% 0% -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 Clodronate (n=320) 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% EQ-5D score 0.9 0.8 0.6 0.7 1 Proportion of Respondents -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 EQ-5D score Hormone replacement therapy (n=755) 35% 30% 25% 20% 15% 10% Proportion of Respondents 5% 0% -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 EQ-5D score Irritable bowel syndrome (n=374) 35% 30% 25% 20% 15% 10% Proportion of Respondents 5% 0% -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 Lower back pain (n=500) 25% 20% 15% 10% 5% 0% EQ-5D score 0.9 0.8 0.6 0.7 1 Proportion of Respondents -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 EQ-5D score Leg Ulcers (n=233) 14% 12% 10% 8% 6% 4% Proportion of Respondents 2% 0% -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 EQ-5D score Leg reconstruction (n=92) 25% 20% 15% 10% Proportion of Respondents 5% 0% -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 Osteoporosis (n=221) 25% 20% 15% 10% 5% 0% EQ-5D score 0.9 0.8 1 Proportion of Respondents -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 EQ-5D score Varicose veins (n=887) 45% 40% 35% 30% 25% 20% 15% Proportion of Respondents 10% 5% 0% -0.3-0.2-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 EQ-5D score

7 Existing evidence Direct methods: Linear regression Tobit (often incorrectly applied!) CLAD Two-part models Poor fit Underestimate at top Overestimate at bottom Biased estimates of treatment effect

8 Methods and models Direct methods: Adjusted Limited Dependent Variable Mixture Model (development of Hernández Alava et al 2012) RE linear regression Indirect method: Set of Generalised Ordered Probits (development of Response Mapping Gray et al 2006)

9 Direct method: Finite Mixture Modelling Useful where simple models don t fit complex data Model data as a finite mixture of component models (usually of the same type) Often used where interest is in identifying clusters of groups But here we are interested in approach because of flexibility Any continuous distribution can be approximated by a mixture of normals

10

11

12

13

14 Don t need to use normal distributions More appropriate bespoke distribution Each component reflects EQ-5D properties Overcomes need for a class of 1 s Combination of: a) Adjusted dist AND b) Mixture framework

15 More formally... Limited at top, with a gap, and bottom Within component (HAQ, HAQ 2, Pain, Age, Age 2) Random effect (gender) Component membership (HAQ, Pain, Pain 2 )

16 Indirect method: Random Effects Generalised Ordered Probit 3 point ordered discrete dependent variable for each of the five dimensions of EQ-5D (RE) Ordered Probit implicit parallel regression assumption too restrictive Multinomial logit model BUT ignores ordinality of the dependent variable

17 Indirect method: Random Effects Generalised Ordered Probits s q it discrete dependent variables for s={mobility, self care, usual activities, pain, anxiety and depression} Expected value calculated mathematically average of all 243 utility values weighted by their estimated probabilities

18 Model selection and comparisons Explanatory variables: HAQ, HAQ 2, pain, gender, age and age 2 BIC to choose number of mixture components 4 MAE & RMSE (insensitive but widely used) Monte Carlo simulation to generate data from models and compare to observed data

19 EQ-5D distribution in each class and overall

20 Distribution of probabilities in each class

21 Table 4: Comparison of Models 1, 2 and 3 N RE linear regression ALDVMM % diff 2 vs 1 RE GOProbit % diff 3 vs 1 % diff 2 vs 3 HAQ 0-1 54,086 MAE 0.0968 0.0854 11.77% 0.0906 6.46% 5.68% RMSE 0.1292 0.1215 5.96% 0.1250 3.22% 2.83% HAQ 1-2 38,307 MAE 0.1571 0.1458 7.17% 0.1515 3.53% 3.77% RMSE 0.2061 0.2025 1.75% 0.2033 1.39% 0.37% HAQ 2-3 8,005 MAE 0.2309 0.2052 11.11% 0.2130 7.77% 3.63% RMSE 0.2626 0.2520 4.01% 0.2543 3.16% 0.88% Overall 100,398 MAE 0.1305 0.1180 9.56% 0.1236 5.30% 4.50% RMSE 0.1752 0.1693 3.37% 0.1713 2.24% 1.16%

22 Only 1% with HAQ>2.5

23

24 Values exceed 1!

25 Does it matter? Example CE model: Rituximab for MTX intolerant patients with RA (Sharma et al. 2009) %diff Inc Costs Inc QALYs ICER base lin base response Linear model 1,952 0.166 11,754 Response 1,952 0.190 10,315 12.2% Mixture 1,952 0.158 12,372-5.3% -19.9%

26 Does it matter? Tentative results only Assume less severe patients %diff Inc Costs Inc QALYs ICER base lin base response Linear model 2,223 0.058 38,441 Response 2,222 0.062 35,903 6.6% Mixture 2,225 0.066 33,535-12.8% -6.6%

27 Conclusion/Discussion Linear models are not appropriate for mapping Response mapping and mixture model approaches substantially better in all regards and it matters! Generalized ordered probit can be used for response mapping Respects ordered nature of data

28 Conclusion/Discussion Bespoke mixture model performs best overall in this example Further work Develop response mapping (correlations, more flexible functional forms) Compare methods in other datasets/simulation/outcomes How will it work with EQ-5D-5L? - Depends how valuations are modelled

29 References Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results from a UK Population Survey. University of York, Centre for health Economics, 1995, Discussion Paper 138. Hernández Alava M, Wailoo AJ, Ara R. Tails from the Peak District: Adjusted Limited Dependent Variable Mixture Models of EQ-5D Health State Utility Values. Value Health 2012; 15: 550-561. Gray A, Rivero-Arias O, Clarke P. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Medical Decision Making 2006; 26(1):18-29. Sharma T., Tosh J., Longworth L., Wailoo A., Akehurst R. (2009) Use Of Rituximab In Patients With Rheumatoid Arthritis With Concomitant Dmards, Or As Monotherapy, For Patients Who Are Intolerant To Methotrexate. Yorkshire and the Humber Specialised Commissioning Group, iedm Report 5/09

To Discover And Understand.